Doxa AB Product Pipeline Analysis

SUMMARY

Doxa AB Product Pipeline Analysis

Summary

This report is an insightful source for data, analysis and strategic insights into a Doxa AB's pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

• Details of development stage by sector and equipment type.
• Pipeline products grouped by therapy area, development stage and trial phase.
• Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
• Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
• Product updates covering estimated approval dates and estimated launch dates.
• Descriptions of novel technologies relating to pipeline products of the company.
• Patents and patent applications covered for the product.
• News updates on key events relating to the product and its development.

Reasons to buy

• A single source to fulfill competitor information relating to products in development.
• Identify pipeline products that are potential competitor to your product lines.
Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.
• Access clinical trial information to map trial results and plan targeted marketing activities.
• Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
• Identification of potential investment opportunities.
• Build up knowledge base for potential distribution and marketing partners.
• Helps avoid patent infringement.
• Timelines from concept to market lets you keep track of market potential build for a new product.
Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

TABLE OF CONTENTS

1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Company Snapshot 8
2.1 Key Information 8
2.2 Company Overview 8
2.3 Industry Outlook -- Orthopedic Devices 8
3 Business Description 9
3.1 Business Overview 9
3.2 Major Products and Services 9
3.2.1 Overview 9
4 History 10
5 Key Employees 11
6 Key Employee Biographies 12
7 Locations And Subsidiaries 13
7.1 Head Office 13
7.2 Other Locations & Subsidiaries 13
8 Recent Developments 14
8.1 Financial Announcements 14
8.1.1 Feb 14, 2008: Doxa Declares Q4 2007 Results 14
8.1.2 Nov 26, 2007: Doxa Declares Q3 2007 Results 15
8.1.3 Sep 03, 2007: Doxa Declares Q2 2007 Results 16
8.1.4 Apr 26, 2007: Doxa Declares Q1 2007 Results 18
8.1.5 Feb 08, 2007: Doxa Declares Q4 2006 Results 19
8.2 Corporate Communications 20
8.2.1 Feb 14, 2008: Doxa Appoints New CEO 20
8.2.2 Jan 07, 2008: Doxa Appoints CEO 20
8.2.3 Jan 15, 2007: Doxa Announces Management Change 20
8.2.4 Jan 15, 2007: Doxa CEO Resigns 21
8.3 Product News 21
8.3.1 Jun 10, 2008: Doxa Files Application For FDA-Registration Of Xeraspine 21
8.3.2 May 23, 2008: Doxa Files Application For Registration Of XeraCem With US Food And Drug Administration, FDA 22
8.3.3 Dec 20, 2007: Important Milestone For Doxa - 59 Patients With Vertebral Fractures Treated With Xeraspine 22
8.3.4 Apr 03, 2007: Doxa Publishes Positive Results Of Clinical Trial For Xeraspine At Griboi-Conference In Oxford 22
8.4 Clinical Trials 23
8.4.1 Dec 20, 2007: Important Milestone For Doxa - 59 Patients With Vertebral Fractures Treated With Xeraspine 23
8.4.2 Apr 03, 2007: Doxa Publishes Positive Results Of Clinical Trial For Xeraspine At Griboi-Conference In Oxford 23
9 Doxa AB Pipeline Products 24
9.1 Doxa AB Product Pipeline Analysis 24
9.1.1 Doxa AB Pipeline Products By Equipment Type 24
9.1.2 Doxa AB Pipeline Products By Development Stage 26
9.1.3 Doxa AB Pipeline Products By Therapy Area 27
9.1.4 Doxa AB Pipeline Products By Clinical Trials 27
9.1.5 Doxa AB Pipeline Products By News Summary 27
9.2 Xeraspine 27
9.2.1 Product Description 28
9.2.2 Product Status 28
9.2.3 Clinical Trials 28
9.2.4 Product Milestone 29
9.3 Doxa 110 29
9.3.1 Product Description 29
9.3.2 Product Status 29
9.4 Doxa 125 30
9.4.1 Product Description 30
9.4.2 Product Status 30
9.5 XeraCem 30
9.5.1 Product Description 30
9.5.2 Product Status 31
9.5.3 Clinical Trials 31
9.5.4 Product Milestone 32
9.6 Doxa 107 (Xeraspine) 32
9.6.1 Product Description 32
9.6.2 Product Status 33
9.6.3 Clinical Trials 33
9.6.4 Product Milestone 34
9.7 Doxa 105-Xeraspine 34
9.7.1 Product Description 34
9.7.2 Product Status 34
10 Appendix 36
10.1 Methodology 36
10.1.1 Coverage 36
10.1.2 Secondary Research 37
10.1.3 Primary Research 37
10.1.4 Expert Panel Validation 38
10.2 Contact Us 38
10.3 About Global Markets Direct 38
10.4 Disclaimer 38

1.1 List of Tables
Table 1: Doxa AB,Key Facts 8
Table 2: Doxa AB, Key Employees, 11
Table 3: Doxa AB, Subsidiaries 13
Table 4: Doxa AB Pipeline Products by Equipment Type 25
Table 5: Doxa AB Pipeline Products By Development Stage 26
Table 6: Doxa AB Pipeline Products By Therapy Area 27
Table 7: Doxa AB Pipeline Products By Clinical Trials 27
Table 8: Doxa AB Pipeline Products By News Summaries 27

1.2 List of Figures
Figure 1: Doxa AB Pipeline Products By Equipment Type 24
Figure 2: Doxa AB Pipeline Products By Equipment Type 25
Figure 3: Doxa AB Pipeline Products By Development Stage 26
Figure 4: Global Markets Direct Methodology 36